TTY Biopharm Company Limited (TPEX:4105)

Market Cap	18.42B
Revenue (ttm)	5.89B
Net Income (ttm)	1.45B
Shares Out	248.65M
EPS (ttm)	5.82
PE Ratio	12.73
Forward PE	15.12
Dividend	4.20 (5.77%)
Ex-Dividend Date	Mar 27, 2025

Volume	685,333
Average Volume	1,032,586
Open	74.50
Previous Close	74.10
Day's Range	74.20 - 75.70
52-Week Range	69.50 - 80.90
Beta	0.19
RSI	31.29
Earnings Date	Mar 11, 2025

About TTY Biopharm Company

TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, and Other Business Unit segments. It offers oncology drugs under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yond...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1960
• Employees: 342
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4105

Financial Performance

In 2024, TTY Biopharm Company's revenue was 5.89 billion, an increase of 7.05% compared to the previous year's 5.51 billion. Earnings were 1.45 billion, an increase of 28.45%.